Akshay Bedmutha, Michal Weiler-Sagie, Leen Alkukhun, Amol Madan Takalkar
Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) serves a multifaceted role across nonlymphoma hematolymphoid disorders, though its utility varies considerably by disease entity. In multiple myeloma, FDG-PET/CT is the International Myeloma Working Group-preferred imaging modality for response assessment, with standardized interpretation through Italian Myeloma criteria for PET Use/Deauville criteria enabling reproducible evaluation. PET-based complete metabolic response and dual imaging-plus-minimal residual disease negativity provide the strongest prognostic stratification, validated across landmark trials including CASSIOPEIA and FORTE. Important limitations include nonavid disease and inferior sensitivity for diffuse marrow infiltration compared to WB-MR imaging, where evidence for combined FDG-PET/MR imaging is gathering.